Pharmaceutical firm Merck & Co has co-led a $26m series D round for US-based cancer care technology provider Navigating Cancer through its Merck Global Health Innovation (GHI) Fund.
The round was co-led by TT Capital Partners, part of healthcare merchant bank TripleTree, and included laboratory services provider LabCorp, Orix Growth Capital, Rustic Canyon Partners and BrightEdge, a fund overseen by the American Cancer Society.
Navigating Cancer’s Patient Relationship Management software helps care providers more effectively engage and communicate with cancer patients, and the proceeds from the series D round will be used to strengthen the platform.
Merck GHI led the company’s last round, a $10m series C in 2015 that also featured Orix Healthcare Capital and Rustic Canyon Partners.
Rustic Canyon provided $2m of funding for Navigating Cancer in 2009 and joined an undisclosed angel investor to add $3m in a 2011 series A round. It received $2.3m in debt financing from Western Technology Investment the following year.
